期刊文献+

电离辐射出血综合征的研究现状

Current research status of ionizing radiation bleeding syndrome
原文传递
导出
摘要 电离辐射引起的出血,涉及原因多,机制较复杂,救治困难;出血更是电离辐射后患者死亡的主要原因之一。本文从血小板异常、凝血障碍、血管受损等方面,综述了电离辐射出血综合征的病理生理机制;从出血程度、出血时间、出血部位等方面,阐述了电离辐射出血综合征的临床特点;结合实验研究结果,提出了治疗电离辐射出血综合征的思路与可能途径,关键因素是尽快促进巨核细胞的恢复和快速产生血小板。 Bleeding caused by ionizing radiation involves many factors,the mechanism is complicated and the management is difficult.Bleeding is recognized as one of the main causes of death after ionizing radiation.In this paper,we summarize the pathophysiological mechanisms of ionizing radiation bleeding syndrome(IRBS)from the aspects of platelet abnormality,coagulation disorder and vascular damage.Besides,we expound the clinical characteristics of IRBS in terms of the degree,time and site of the bleeding.Combined with experimental results,we put forward ideas and possible approaches for the treatment of IRBS,and the key factor is to promote the recovery of megakaryocytes and rapid platelet production after radiation exposure.
作者 王鑫淼 王军平 冉新泽 WANG Xinmiao;WANG Junping;RAN Xinze(Institute of Combined Injury,Army Military Medical University,State Key Laboratory of Trauma,Burns and Combined Injury,Chongqing 400038 China)
出处 《中国辐射卫生》 2021年第4期524-528,共5页 Chinese Journal of Radiological Health
关键词 电离辐射 出血 血小板 Ionizing Radiation Hemorrhage Platelet
  • 相关文献

参考文献4

二级参考文献45

  • 1Buddai SK, Toulokhonova L, Bergum PW, et al. Nematode anticoagulant protein c2 reveals a site on factor X a that is important for macromolecular substrate binding to human prothrombinase[J]. J Biol Chem, 2002,277:26689
  • 2Moons AH, Peters RJ, Bijsterveld NR, et al. Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor Ⅶa complex, in patients undergoing elective coronary angioplasty [J]. J Am Coil Cardiol,2003,41:2147
  • 3Hirayama F, Koshio H, Ishihara T, et al. Design, synthesis and biological activity of YM-60828 derivatives: potent and orally-bioavailable factor X a inhibitors based on naphthoanilide and naphthalensulfonanilide templates.Bioorg Med Chem, 2002,10:2597
  • 4Abendschein DR, Baum PK, Verhallen P, et al. A novel synthetic inhibitor of factor X a decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs[J]. J Pharmacol Exp Ther, 2001,296(2):567
  • 5Uhlrich S, Lagente O, Choay J, et al. Structure activity relationship in heparin: stimulation of non-vascular cells by a synthetic heparin pentasaccharide in cooperation with human acidic fibroblast growth factors [J]. Biochem Biophys Res Commun, 1986,139
  • 6Vuillemenot A, Schiele F, Meneveau N, et al. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent--a pilot study in the setting of coronary angioplasty[J]. Thromb Haemost, 1999,81:214
  • 7Schaffer LW, Davidson JT, Vlasuk GP, et al. Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis[J]. Circulation, 1991,84:1741
  • 8Dunwiddie CT, Nutt EM, Vlasuk GP, et al. Anticoagulant efficacy and immunogenicity of the selective factor Xa inhibitor antistasin following subcutaneous administration in the rhesus monkey[J]. Thromb Haemost, 1992,67:371
  • 9Waxman L, Smith DE, Arcuri KE, et al. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa[J]. Science, 1990,248:593
  • 10Weitz, JI, Hirsh J. New Anticoagulant Drugs[J]. Chest, 2001,119: 95S

共引文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部